+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 10 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
S

Actively Recruiting

Researchers are evaluating zolbetuximab combined with pembrolizumab and chemotherapy in adults with stomach cancer or gastroesophageal junction GEJ cancer that is HER2-negative, Claudin 18.2-positive, and PD-L1-positive. The study focuses on people with locally advanced unresectable or metastatic disease who may have had prior standard treatments. This phase 3 randomized, double-blind study aims to understand how well zolbetuximab works with other therapies compared to placebo with pembrolizumab and chemotherapy. Participants receive either zolbetuximab or placebo intravenously every 2 or 3 weeks, along with pembrolizumab infusions every 3 or 6 weeks. Chemotherapy is given as either CAPOX oral capecitabine tablets and oxaliplatin infusions or mFOLFOX6 infusions of oxaliplatin, folinic acid, and 5-fluorouracil over several cycles. Treatment continues until cancer progression, intolerable side effects, or another cancer therapy is needed. Pembrolizumab may be given for up to 2 years. During the study, participants visit clinics for treatment infusions, health checks, and scans to monitor cancer changes. Medical problems and side effects are tracked, and tumor samples may be collected if treatment stops due to progression. Follow-up visits and telephone health checks continue after treatment to monitor participants health and cancer status. The study measures overall survival as the main outcome over up to 72 months.

Age: 18Years +All GendersPhase 3
252 locations
C

Actively Recruiting

Researchers are evaluating different treatments for patients with bifurcation coronary artery disease affecting vessels larger than 2.0 mm in diameter. This international, multicenter, randomized clinical trial includes patients needing percutaneous coronary intervention PCI for stable coronary artery disease or acute coronary syndrome. The study compares two types of drug-coated balloons Paclitaxel and Sirolimus with new generation drug-eluting stents DES to assess their effects on bifurcation lesions. Participants will be randomly assigned to one of three groups Paclitaxel drug-coated balloons, Sirolimus drug-coated balloons, or standard treatment with new generation drug-eluting stents. After successful lesion preparation, the assigned device will be used following standard coronary angioplasty procedures. The study is open-label, meaning both patients and doctors know the treatment given. The research team follows international guidelines and local practices during the procedure. During the study, participants will have follow-up assessments including CT-FFR or invasive FFR at 6 to 9 months to measure artery narrowing at the treated bifurcation. Additional outcomes such as major adverse cardiac events, cardiac and all-cause death, myocardial infarction, vessel revascularization, thrombosis, and bleeding are monitored up to about 24 months. Patients will be evaluated regularly to track safety and the effectiveness of the treatments over time.

Age: 18Years +All GendersPhase Not Applicable
17 locations
S

Actively Recruiting

Researchers are analyzing outcomes from patients who underwent percutaneous coronary intervention PCI for coronary artery disease involving bifurcation lesions. The study compares two different two-stent techniques the Culotte technique and the Double Kiss DK Culotte technique. This retrospective study uses data collected from two high-volume cardiac centers in the Lower Silesia Region between April 2012 and January 2024. The choice of which stent technique to use was made by the treating physician based on clinical and angiographic factors, with no restrictions on lesion characteristics. Patients included had bifurcation lesions treated with either the classical Culotte technique or the DK-Culotte technique, which involves an additional balloon dilation step after side branch stenting. The study groups consist of patients treated with one of these two stenting methods. The PCI was performed following standard clinical indications, with all patients informed about treatment options and risks before consenting. Patients who had previous stenting of the same bifurcation lesion before the procedure were excluded. Participants outcomes are monitored retrospectively over a 5-year period following their initial hospital stay. The primary outcome measured is target lesion failure, with evaluations every 6 months after hospital discharge. Secondary outcomes include major adverse cardiac events MACE. This long-term follow-up allows researchers to assess the safety and effectiveness of the two-stent techniques over time using clinical records and data analysis.

Age: 18Years +All Genders
2 locations
L

Actively Recruiting

This research involves patients with chronic disabling refractory angina pectoris classified as Canadian Cardiovascular Society CCS classes 2-4. These patients have persistent angina despite receiving the maximum tolerated anti-angina medical therapy and are not suitable for percutaneous or surgical revascularization. The study aims to evaluate the long-term safety and effectiveness of the Coronary Sinus Reducer device in this group of patients through a single-center, single-arm registry. Participants undergo implantation of the Coronary Sinus Reducer, a balloon-expandable, hourglass-shaped scaffold that is placed percutaneously into the coronary sinus via the venous system. This device narrows the coronary sinus to delay blood outflow. After implantation, patients receive a follow-up visit one month later, then clinical assessments every six months over an observation period extending up to five years. During the study, participants will have initial evaluations including medical history, clinical assessment of angina severity by CCS class, Seattle Angina Questionnaire scores, a 6-minute walk test, and echocardiography. The main outcomes measured will be the reduction in angina symptoms one year after device implantation. Secondary outcomes include adverse events, changes in aerobic capacity and endurance, and improvement in quality of life. Clinical follow-up will continue for up to five years to monitor safety and efficacy.

Age: 18Years +All Genders
2 locations
S

Actively Recruiting

This research focuses on patients with moderately to severely calcified lesions in their coronary arteries who undergo percutaneous coronary intervention PCI. The study aims to collect data on the safety and effectiveness of PCI when supported by the Orbital Atherectomy Device. Patients are selected based on clinical indication according to current European Society of Cardiology guidelines and the presence of significant calcification assessed by angiography or intravascular imaging techniques like IVUS or OCT. The study involves patients treated at two cardiac centers in Poland where the decision to use the Orbital Atherectomy Device during PCI is made by the operator based on lesion characteristics. Moderate calcification is defined as involving 30% to 50% of the lesion diameter, while severe calcification involves more than 50%. The procedure details, including additional lesion preparation, stent implantation, medication, and imaging use, are determined by the treating physician. All patients give informed consent after being advised about treatment options and risks. Participants will be monitored at discharge up to 10 days to assess clinical success and any treatment-emergent adverse events. Long-term follow-up includes evaluation of major adverse cardiac and cerebrovascular events for up to five years after hospitalization, with assessments every six months. The study collects comprehensive data on treatment outcomes and safety during and after the procedure, supporting ongoing patient care and research.

Age: 18Years +All Genders
2 locations
R

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and clinical outcomes of percutaneous coronary intervention PCI for chronic total occlusions CTO in patients treated in routine clinical practice in Poland. The study seeks to understand procedural success rates, complications, and how different PCI strategies, intravascular imaging, mechanical support, and artificial intelligence analysis impact patient outcomes and quality of life. It also focuses on outcomes in various patient subgroups, including those with complex medical histories. This observational study enrolls patients undergoing CTO PCI as part of their standard care in a national, multicenter registry. Clinical, procedural, and follow-up data are collected prospectively to assess real-world outcomes. The study compares PCI performed with and without intravascular imaging and evaluates different treatment strategies such as drug-coated balloons, drug-eluting stents, and hybrid approaches. It also monitors the use of mechanical circulatory support and applies AI-based analysis of baseline electrocardiograms for outcome prediction. Participants will be followed to measure technical success of the procedure and monitor procedural details such as procedure time, fluoroscopy time, radiation dose, contrast volume, and procedural complications within one day. Additional outcomes include target lesion failure during hospital stay and up to one year, as well as mortality at one year. The study collects information on post-procedure cardiac injury markers and quality-of-life improvements, with data gathered throughout routine clinical care over the follow-up period.

Age: 18Years +All Genders
21 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System in people with coronary artery disease who have atherosclerotic lesions longer than 36 mm and up to 44 mm in their native coronary arteries. The study focuses on lesions with a reference vessel diameter between 2.25 mm and 4.0 mm. This is a prospective, multicenter, single-arm study sponsored by Teleflex, aiming to treat subjects with these specific lesions using this device. Participants will receive the Orsiro Mission stent, which consists of a cobalt chromium stent platform coated with a bioabsorbable polymer containing the drug sirolimus. This device is designed to be implanted in the coronary arteries during percutaneous coronary intervention PCI. The study involves a single group receiving this stent to assess its performance in treating lesions of the specified length and size. During the study, participants will have follow-up visits to monitor outcomes and safety. Those enrolled in the United States will be followed for 2 years with visits at 1, 6, 12 months, and 2 years after the procedure. Participants outside the United States will be followed for 5 years with additional visits at 3 and 5 years. Researchers will measure target lesion failure at 12 months as the primary outcome and will also track device and procedure success, deaths, heart attacks, major cardiac events, revascularizations, and stent thrombosis throughout the follow-up period.

Age: 18Years +All GendersPhase Not Applicable
23 locations
C

Actively Recruiting

Coronary artery disease occurs when the arteries narrow, sometimes requiring a procedure called Percutaneous Coronary Intervention PCI to open them. This study focuses on treating calcified coronary artery lesions, which can make stent placement difficult. Researchers are comparing two devices that use sonic pressure waves to break up calcified plaques the newer ShockFast IVL and the more established Shockwave IVL. The trial aims to assess how these devices perform in treating these challenging lesions. Participants receive treatment with one of two devices during PCI. The ShockFast IVL device uses sonic pressure waves to safely fracture calcium deposits, aiming to keep the artery flexible and allow smoother stent placement. It offers an improved crossing profile and two catheter lengths. The Shockwave IVL device also uses sonic pressure waves but has only one catheter length. Both devices are used during the coronary intervention procedure to modify calcified plaques. During the study, participants undergo PCI with one of the two devices. Researchers measure the stent area at the narrowest artery point during the procedure using optical coherence tomography OCT. Additional outcomes include target lesion failure, angiographic success, and device success assessed up to 30 days after the procedure. The study involves hospital assessments during the procedure and follow-up visits over 30 days to monitor safety and effectiveness. The trial is expected to complete by March 2027.

Age: 18Years +All GendersPhase Not Applicable
13 locations
S

Actively Recruiting

The Lower Silesia Shockwave Registry LSSR is an observational study collecting data on patients undergoing percutaneous coronary intervention PCI with the support of shockwave intravascular lithotripsy S-IVL in two cardiac centers in Poland. The study includes patients with highly calcified, resistant lesions or significantly under-expanded previously implanted stents, aiming to evaluate the safety and effectiveness of this device in improving stent deployment and vessel preparation. Patients in the registry received PCI supported by the S-IVL device, with operators deciding the initial lesion preparation and catheter size based on angiographic and optional intravascular imaging assessments. Drug-eluting stents or balloons were used at the operators discretion. The study does not restrict lesion anatomy and includes cases where advanced debulking procedures were initially performed. Clinical success and safety outcomes are measured, including effective stent deployment and serious angiographic complications. Participants are monitored during their hospital stay and followed up every six months for up to five years to track major adverse cardiac and cerebrovascular events MACCE such as death, myocardial infarction, stroke, or repeated revascularization. Data collection includes clinical evaluations by medical staff in person or by phone. The study has ethical approval and aims to provide long-term safety and efficacy data on using shockwave intravascular lithotripsy in coronary artery disease treatment.

Age: 18Years - 99YearsAll Genders
2 locations